What's new

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 26, Status: Authorised

Jun 10, 2025 - 16:25
 0
Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 26, Status: Authorised
Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 26, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Rozlytrek, entrectinib...

Next Article

Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, Mirikizumab, d...

Related Posts

PSUSA/00000795/202410

PSUSA/00000795/202410

Jun 5, 2025  0

Orphan designation: Ganaxolone Treatment of CDKL5 deficiency disorder, 13/11/2019 Positive

Orphan designation: Ganaxolone Treatment of CDKL5 defic...

Jun 5, 2025  0

Human medicines European public assessment report (EPAR): Ovitrelle, choriogonadotropin alfa, Date of authorisation: 02/02/2001, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR...

May 23, 2025  0